|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Unité de Recherche sur les Obésités, Institut National de la Santé et de la Recherche Médicale, Institut Louis Bugnard, Hôpital Rangueil, Université Paul Sabatier, Toulouse, France (V.B., A.Z.-G., S.D.B., C.P., V.D.d.S.F., M.L., J.G.); and Institut für Kardiovaskuläre Physiologie, Frankfurt/Main, Germany (A.B.)
We previously showed that human and murine 3T3-F442A preadipocytes produced and released matrix metalloproteinases (MMPs) 2 and 9 and that a treatment by MMP inhibitors resulted in the blockade of murine fat cell adipose conversion. In parallel, investigators reported that other protease inhibitors, the human immunodeficiency virus (HIV) protease inhibitors (PIs) involved in lipodystrophy in humans, also reduced the adipocyte differentiation process of several murine cell lines. The present work was performed to define the effects of MMP inhibitors and HIV-PIs on the human adipocyte differentiation process, to clarify the involvement of MMPs in the control of human adipogenesis, and to determine whether HIV-PIs interact with MMPs in the control of this process. The effect of two MMP inhibitor and four HIV-PI treatments on the differentiation of primary culture human preadipocytes, as well as the putative relationships between HIV-PIs and MMP-2 and -9 expression, release, or activity were investigated. We showed that MMP inhibitors and HIV-PIs reduced the human adipocyte differentiation process as assessed by the decrease of cell protein and/or triglyceride contents and expression of fatty acid binding protein and hormone-sensitive lipase, two adipocyte markers. Unlike MMP inhibitors, HIV-PIs were devoid of any effect per se on recombinant MMP-2 and 9 activities but reduced the expression and release of MMP-9 by human preadipocytes. Thus, the present study indicates that the modulation of the extracellular matrix components through the production and/or activity of MMPs, and, more precisely, MMP-9 might be a key factor in the regulation of human adipose tissue development.
Address correspondence to: Dr. Virginie Bourlier, Institut National de la Santé et de la Recherche Médicale U586, 37 Allées Jules Guesde, 31073 Toulouse, France. E-mail: virginie.bourlier{at}cict.fr
This article has been cited by other articles:
![]() |
L. C. Chao, S. J. Bensinger, C. J. Villanueva, K. Wroblewski, and P. Tontonoz Inhibition of Adipocyte Differentiation by Nur77, Nurr1, and Nor1 Mol. Endocrinol., December 1, 2008; 22(12): 2596 - 2608. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu and C. M. Smas Wdnm1-like, a new adipokine with a role in MMP-2 activation Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E205 - E215. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Lijnen Angiogenesis and obesity Cardiovasc Res, May 1, 2008; 78(2): 286 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bourlier, A. Zakaroff-Girard, A. Miranville, S. De Barros, M. Maumus, C. Sengenes, J. Galitzky, M. Lafontan, F. Karpe, K.N. Frayn, et al. Remodeling Phenotype of Human Subcutaneous Adipose Tissue Macrophages Circulation, February 12, 2008; 117(6): 806 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Muratori, A. Sistigu, E. Ruggiero, M. Falchi, I. Bacigalupo, C. Palladino, E. Toschi, and M. Federico Macrophages Transmit Human Immunodeficiency Virus Type 1 Products to CD4-Negative Cells: Involvement of Matrix Metalloproteinase 9 J. Virol., September 1, 2007; 81(17): 9078 - 9087. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. De Barros, A. Zakaroff-Girard, M. Lafontan, J. Galitzky, and V. Bourlier Inhibition of Human Preadipocyte Proteasomal Activity by HIV Protease Inhibitors or Specific Inhibitor Lactacystin Leads to a Defect in Adipogenesis, Which Involves Matrix Metalloproteinase-9 J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 291 - 299. [Abstract] [Full Text] [PDF] |
||||